---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-018455"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-07-05T23:59:59+00:00"
generated_at: "2026-06-24T21:25:30.570544+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)

## Summary
- Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.
- Only 10% (50mg) and 30% (100mg) reported feeling high vs 75% placebo (p<0.001).
- ANEB-001 well tolerated; all AEs mild/transient except one moderate nausea/vomiting in 50mg group.
- Part B of study planned for Q3 2022; U.S. IND submission expected by end of 2022.
- Conference call at 8:30am ET today to discuss topline results.

## SEC filing metadata
- accession: 0001493152-22-018455
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/0001493152-22-018455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-018455
- JSON: https://secwatch.observer/filing/0001493152-22-018455.json
- Plain text: https://secwatch.observer/filing/0001493152-22-018455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.